Tech Company Financing Transactions
Biomea Fusion Funding Round
On 1/7/2021, Biomea Fusion received $56 million in Series A financing from Cormorant Asset Management, Aisling Capital and Boxer Capital.
Transaction Overview
Company Name
Announced On
1/7/2021
Transaction Type
Venture Equity
Amount
$56,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds from the financing will support Biomea Fusion to bring its irreversible menin inhibitor into the clinic to produce first-in-human data for a variety of tumor types.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
726 Main St. Chamberlain Building
Redwood City, CA 94063
USA
Redwood City, CA 94063
USA
Phone
Website
Email Address
Overview
We are a precision oncology company developing novel small molecules that target aggressive forms of cancer. Patients with these aggressive tumors typically exhibit high mortality rates and suffer from inadequate treatment options. We are dedicated to developing innovative medicines for patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Thomas Butler
Chief Information Officer
Anthony Souza
President
Ramses Erdtmann
Vice President
Taisei Kinoshita
Vice President
Thorsten Kirschberg
VP - Finance
Sunny Ryan
VP - Operations
Naomi Cretcher
Browse more venture capital transactions:
Prev: 1/7/2021: mindzie venture capital transaction
Next: 1/7/2021: Hinge Health venture capital transaction
Share this article
About Database of VC Transactions
We do our best to record every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs